4D Molecular Therapeutics (FDMT) Projected to Release Quarterly Earnings on Tuesday

4D Molecular Therapeutics (NASDAQ:FDMT) is projected to post its Q3 2026 resultson Tuesday, November 10th. Analysts expect 4D Molecular Therapeutics to post earnings of ($1.04) per share and revenue of $4.13 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, analysts expect 4D Molecular Therapeutics to post ($4.14) EPS for the current fiscal year and ($4.09) EPS for the next fiscal year.

4D Molecular Therapeutics Stock Up 5.0%

FDMT stock traded up $0.56 during mid-day trading on Tuesday, reaching $11.94. 241,587 shares of the company traded hands, compared to its average volume of 862,804. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average price is $13.63 and its 200 day moving average price is $10.88. The stock has a market cap of $659.34 million, a price-to-earnings ratio of -4.55 and a beta of 2.75. 4D Molecular Therapeutics has a fifty-two week low of $6.96 and a fifty-two week high of $16.93.

Insider Activity at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the transaction, the insider owned 709,153 shares in the company, valued at approximately $9,162,256.76. This represents a 7.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders sold 123,790 shares of company stock worth $1,655,545. Insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on FDMT. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, October 22nd. Bank of America raised their price objective on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price objective on the stock in a report on Monday, September 14th. Finally, Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, October 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.